Skip to main content
Gregory Wolf, MD, Otolaryngology (ENT), Ann Arbor, MI

GregoryTWolfMD

Otolaryngology (ENT) Ann Arbor, MI

Head & Neck Oncologic Surgery, Head & Neck Plastic Surgery, Facial Plastic Surgery

Professor of Otolaryngology, University Mich Medical School

Dr. Wolf is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Wolf's full profile

Already have an account?

  • Office

    1500 E Medical Center Dr
    # 1
    Ann Arbor, MI 48109
    Phone+1 734-936-8051

Education & Training

  • National Cancer Institute
    National Cancer InstituteFellowship, Tumor Immunology, 1978 - 1980
  • SUNY Upstate Medical University
    SUNY Upstate Medical UniversityResidency, Otolaryngology - Head and Neck Surgery, 1975 - 1978
  • MedStar Health/Georgetown-Washington Hospital
    MedStar Health/Georgetown-Washington HospitalResidency, Surgery, 1973 - 1975
  • District of Columbia General Hospital
    District of Columbia General HospitalResidency, Surgery, 1974 - 1974
  • University of Michigan Medical School
    University of Michigan Medical SchoolClass of 1973

Certifications & Licensure

  • MI State Medical License
    MI State Medical License 1980 - 2023
  • American Board of Otolaryngology - Head and Neck Surgery Otolaryngology

Awards, Honors, & Recognition

  • Alpha Omega Alpha
  • Albert Nelson Marquis Lifetime Achievement Award 2018
  • President, American Head and Neck Society 2012
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • IRX Therapeutics Presents Positive IRX-2 Phase 2a Head and Neck Squamous Cell Carcinoma Clinical Results at the European Society for Medical Oncology Annual Congress 2017
    IRX Therapeutics Presents Positive IRX-2 Phase 2a Head and Neck Squamous Cell Carcinoma Clinical Results at the European Society for Medical Oncology Annual Congress 2017September 11th, 2017
  • Individualized Bioselection Treatment Methods Increase Survival Rates in Laryngeal Cancer
    Individualized Bioselection Treatment Methods Increase Survival Rates in Laryngeal CancerFebruary 13th, 2017

Grant Support

  • Co-investigator (5%) - Develop a Therapeutic Nano-vaccine against Head and Neck Cancer.NIH2018–2023
  • Co-Investigator (5%) - Statistical Methods for Cancer Biomarkers.NIH2017–2022
  • Co-Investigator (5%) - Development of a Prognostic Compound Immunoscore for Head and Neck CancerNIH2018–2020
  • Principal Investigator (50%) - Central Laboratory and Biorepository for INSPIRE: A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy with the IRX-2 Regimen in Patients with Newly DiagnoseBrooklyn Immunotherapeutics, Inc2015–2020
  • The Molecular Basis Of Head And Neck Cancer Biology, Treatment And PreventionNational Cancer Institute2008–2011
  • Role Of Soy Isoflavones, Smoking Abstinence And Molecular Markers In PreventionNational Cancer Institute2008–2011
  • Developmental Research ProgramNational Cancer Institute2008–2011
  • Career Development ProgramNational Cancer Institute2008–2011
  • C1: AdministrationNational Cancer Institute2008–2011
  • The Molecular Basis Of Head And Neck Cancer TherapyNational Cancer Institute2002–2007
  • Advanced Research Training In OtolaryngologyNational Institute On Deafness And Other Communication Disorders2002–2006
  • Research Training In The Communicative SciencesNational Institute On Deafness And Other Communication Disorders1995–2001

Professional Memberships